SCHEMBL4665748

SCHEMBL4665748

COc1ccc(S(=O)(=O)N(OC=O)c2ccc(Nc3cc(-c4ccc(OCC5CCN(C)CC5)c(F)c4)ncn3)cc2)cc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 13/20 0.42
KDR P35968 5/20 0.39
MET P08581 3/20 0.39
IKBKE Q14164 2/20 0.38
TBK1 Q9UHD2 2/20 0.38
KIT P10721 2/20 0.37
FGFR1 P11362 2/20 0.36
FLT1 P17948 2/20 0.36
FLT4 P35916 2/20 0.36
BMPR1B O00238 1/20 0.36
PLK4 O00444 1/20 0.36
CIT O14578 1/20 0.36
GAK O14976 1/20 0.36
EPHB6 O15197 1/20 0.36
RIPK2 O43353 1/20 0.36
ROCK2 O75116 1/20 0.36
STK10 O94804 1/20 0.36
MAP4K4 O95819 1/20 0.36
ABL1 P00519 1/20 0.36
ERBB2 P04626 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4664277 0.97 EGFR (0.43) EGFRKDRMETIKBKETBK1
SCHEMBL4666156 0.95 EGFR (0.41) EGFRKDRMETIKBKETBK1
SCHEMBL4663941 0.94 EGFR (0.40) EGFRKDRABL1BCR
SCHEMBL4665787 0.94 ABL1 (0.41) EGFRKDRMETABL1BCR
SCHEMBL4665886 0.93 EGFR (0.37) EGFRKDRIKBKETBK1FGFR1
SCHEMBL4667543 0.89 EGFR (0.39) EGFRKDRMETIKBKETBK1
SCHEMBL4665829 0.89 EGFR (0.39) EGFRKDRMETIKBKETBK1
SCHEMBL4665766 0.89 EGFR (0.44) EGFRABL1BCR
SCHEMBL4665796 0.89 EGFR (0.44) EGFRKDRIKBKETBK1FGFR1
SCHEMBL4667481 0.89 PIK3R1 (0.42) EGFRKDRMETIKBKETBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 EGFR 279/4885KDR 431/4885MET 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.